2 documents found, page 1 of 1
Psychometric properties of clinical indicators for identification and managemen...
Antonini, Angelo; Pahwa, Rajesh; Odin, Per; Henriksen, Tove; Soileau, Michael J.; Rodriguez-Cruz, Ramon; Isaacson, Stuart H.; Merola, AristideIntroduction: Standardized and validated criteria to define advanced Parkinson’s disease (PD) or identify patient eligibility for device-aided therapy are needed. This study assessed the psychometric properties of clinical indicators of advanced PD and eligibility for device-aided therapy in a large population. Methods: This retrospective analysis of the Adelphi Parkinson’s Disease Specific Programme collected ...
Efficacy results of pimavanserin from a multi-center, open-label extension stud...
Isaacson, Stuart H.; Ballard, Clive G.; Kreitzman, David L.; Coate, Bruce; Norton, James C.; Fernandez, Hubert H.; Ilic, Tihomir V.Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated with Parkinson's disease psychosis (PDP). We present durability of response with pimavanserin in patients with PDP for an additional 4 weeks of treatment. Methods: This was an open-label extension (OLE) study in patients previously completing one of three double-blind, placebo-cont...